|
1.
|
Youlden DR, Cramb SM and Baade PD: The
international epidemiology of lung cancer: geographical
distribution and secular trends. J Thorac Oncol. 3:819–831. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Ferraldeschi R, Baka S, Jyoti B, et al:
Modern management of small-cell lung cancer. Drugs. 67:2135–2152.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Simon GR and Turrisi A; American College
of Chest Physicians: Management of small cell lung cancer: ACCP
evidence-based clinical practice guidelines (2nd edition). Chest.
132(Suppl 3): 324S–339S. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Sangha R, Lara PN Jr, Adjei AA, et al:
Cooperative group research endeavors in small-cell lung cancer:
current and future directions. Clin Lung Cancer. 10:322–330. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5.
|
Planchard D and Le Péchoux C: Small cell
lung cancer: new clinical recommendations and current status of
biomarker assessment. Eur J Cancer. 47(Suppl 3): S272–S283. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Abrams TJ, Lee LB, Murray LJ, et al:
SU11248 inhibits KIT and platelet-derived growth factor receptor
beta in preclinical models of human small cell lung cancer. Mol
Cancer Ther. 2:471–478. 2003.PubMed/NCBI
|
|
7.
|
Sher T, Dy GK and Adjei AA: Small cell
lung cancer. Mayo Clin Proc. 83:355–367. 2008. View Article : Google Scholar
|
|
8.
|
Chen G, Huynh M, Fehrenbacher L, et al:
Phase II trial of irinotecan and carboplatin for extensive or
relapsed small-cell lung cancer. J Clin Oncol. 27:1401–1404. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9.
|
Go RS and Adjei AA: Review of the
comparative pharmacology and clinical activity of cisplatin and
carboplatin. J Clin Oncol. 17:409–422. 1999.PubMed/NCBI
|
|
10.
|
Iwasaki Y, Nagata K, Nakanishi M, et al:
Double-cycle, high-dose ifosfamide, carboplatin, and etoposide
followed by peripheral blood stem-cell transplantation for small
cell lung cancer. Chest. 128:2268–2273. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Kosmas C, Tsavaris NB, Malamos NA, et al:
Phase II study of paclitaxel, ifosfamide, and cisplatin as
second-line treatment in relapsed small-cell lung cancer. J Clin
Oncol. 19:119–126. 2001.PubMed/NCBI
|
|
12.
|
Spiro SG, Tanner NT, Silvestri GA, et al:
Lung cancer: progress in diagnosis, staging and therapy.
Respirology. 15:44–50. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Mela GS, Cimmino MA and Ugolini D: Impact
assessment of oncology research in the European Union. Eur J
Cancer. 35:1182–1186. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Li WT and Yang YN: Zipf’s law in
importance of genes for cancer classification using microarray
data. J Theor Biol. 219:539–551. 2002.
|
|
15.
|
Grossi F, Belvedere O and Rosso R:
Geography of clinical cancer research publications from 1995 to
1999. Eur J Cancer. 39:106–111. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Cimmino MA, Maio T, Ugolini D, et al:
Trends in otolaryngology research during the period 1995–2000: a
bibliometric approach. Otolaryngol Head Neck Surg. 132:295–302.
2005.
|
|
17.
|
Cambrosio A, Keating P, Mercier S, et al:
Mapping the emergence and development of translational cancer
research. Eur J Cancer. 42:3140–3148. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Bingley AF, McDermott E, Thomas C, et al:
Making sense of dying: a review of narratives written since 1950 by
people facing death from cancer and other diseases. Palliat Med.
20:183–195. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Rada R: Characterizing cancer information
systems. J Med Syst. 30:153–157. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Ugolini D, Puntoni R, Perera FP, et al: A
bibliometric analysis of scientific production in cancer molecular
epidemiology. Carcinogenesis. 28:1774–1779. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Klar M, Földi M, Denschlag D, et al:
Estimates of global research productivity in gynecologic oncology.
Int J Gynecol Cancer. 19:489–493. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22.
|
Glynn RW, Scutaru C, Kerin MJ, et al:
Breast cancer research output, 1945–2008: a bibliometric and
density-equalizing analysis. Breast Cancer Res. 12:R1082010.
|
|
23.
|
Ugolini D, Neri M, Casilli C, et al: A
bibliometric analysis of scientific production in mesothelioma
research. Lung Cancer. 70:129–135. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Ho YS, Satoh H and Lin SY: Japanese lung
cancer research trends and performance in Science Citation Index.
Intern Med. 49:2219–2228. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Lewison G, Purushotham A, Mason M, et al:
Understanding the impact of public policy on cancer research: A
bibliometric approach. Eur J Cancer. 46:912–919. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Suk FM, Lien GS, Yu TC and Ho YS: Global
trends in Helicobacter pylori research from 1991 to 2008
analyzed with the Science Citation Index Expanded. Eur J
Gastroenterol Hepatol. 23:295–301. 2011.
|
|
27.
|
Lin HW, Yu TC and Ho YS: A systemic review
of human papillomavirus studies: global publication comparison and
research trend analyses from 1993 to 2008. Eur J Gynaecol Oncol.
32:133–140. 2011.PubMed/NCBI
|
|
28.
|
Micheli A, Di Salvo F, Lombardo C, et al:
Cancer research performance in the European Union: a study of
published output from 2000 to 2008. Tumori. 97:683–689.
2011.PubMed/NCBI
|
|
29.
|
Li LL, Ding G, Feng N, et al: Global stem
cell research trend: bibliometric analysis as a tool for mapping of
trends from 1991 to 2006. Scientometrics. 80:39–58. 2009.
View Article : Google Scholar
|
|
30.
|
Mao N, Wang MH and Ho YS: A bibliometric
study of the trend in articles related to risk assessment published
in Science Citation Index. Human Ecol Risk Assess. 16:801–824.
2010. View Article : Google Scholar
|
|
31.
|
Zhang GF, Xie SD and Ho YS: A bibliometric
analysis of world volatile organic compounds research trends.
Scientometrics. 83:477–492. 2010. View Article : Google Scholar
|
|
32.
|
Li T, Ho YS and Li CY: Bibliometric
analysis on global Parkinson’s disease research trends during
1991–2006. Neurosci Lett. 441:248–252. 2008.
|
|
33.
|
Chen SR, Chiu WT and Ho YS: Asthma in
children: mapping the literature by bibliometric analysis. Rev Fr
Immunol Clin. 45:442–446. 2005.
|
|
34.
|
Han JS and Ho YS: Global trends and
performances of acupuncture research. Neurosci Biobehav Rev.
35:680–687. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35.
|
Malarvizhi R, Wang MH and Ho YS: Research
trends in adsorption technologies for dye containing wastewaters. W
Appl Sci J. 8:930–942. 2010.
|
|
36.
|
Bhandari M, Busse JW, Kulkarni AV, et al:
Interpreting authorship order and corresponding authorship.
Epidemiol. 15:125–126. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37.
|
Burman KD: ‘Hanging from the masthead’:
reflections on authorship. Ann Intern Med. 97:602–605. 1982.
|
|
38.
|
Crystal AS and Shaw AT: New targets in
advanced NSCLC: EML4-ALK. Clin Adv Hematol Oncol. 9:207–214.
2011.PubMed/NCBI
|
|
39.
|
Schmittel A: Second-line therapy for
small-cell lung cancer. Exp Rev of Anticancer Ther. 11:631–637.
2011. View
Article : Google Scholar : PubMed/NCBI
|
|
40.
|
Jotte R, Conkling P, Reynolds C, et al:
Randomized phase II trial of single-agent amrubicin or topotecan as
second-line treatment in patients with small-cell lung cancer
sensitive to first-line platinum-based chemotherapy. J Clin Oncol.
29:287–293. 2011. View Article : Google Scholar : PubMed/NCBI
|
